Literature DB >> 24891139

Loss of dopamine phenotype among midbrain neurons in Lesch-Nyhan disease.

Martin Göttle1, Cecilia N Prudente, Rong Fu, Diane Sutcliffe, Hong Pang, Deborah Cooper, Emir Veledar, Jonathan D Glass, Marla Gearing, Jasper E Visser, H A Jinnah.   

Abstract

OBJECTIVE: Lesch-Nyhan disease (LND) is caused by congenital deficiency of the purine recycling enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGprt). Affected patients have a peculiar neurobehavioral syndrome linked with reductions of dopamine in the basal ganglia. The purpose of the current studies was to determine the anatomical basis for the reduced dopamine in human brain specimens collected at autopsy.
METHODS: Histopathological studies were conducted using autopsy tissue from 5 LND cases and 6 controls. Specific findings were replicated in brain tissue from an HGprt-deficient knockout mouse using immunoblots, and in a cell model of HGprt deficiency by flow-activated cell sorting (FACS).
RESULTS: Extensive histological studies of the LND brains revealed no signs suggestive of a degenerative process or other consistent abnormalities in any brain region. However, neurons of the substantia nigra from the LND cases showed reduced melanization and reduced immunoreactivity for tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis. In the HGprt-deficient mouse model, immunohistochemical stains for TH revealed no obvious loss of midbrain dopamine neurons, but quantitative immunoblots revealed reduced TH expression in the striatum. Finally, 10 independent HGprt-deficient mouse MN9D neuroblastoma lines showed no signs of impaired viability, but FACS revealed significantly reduced TH immunoreactivity compared to the control parent line.
INTERPRETATION: These results reveal an unusual phenomenon in which the neurochemical phenotype of dopaminergic neurons is not linked with a degenerative process. They suggest an important relationship between purine recycling pathways and the neurochemical integrity of the dopaminergic phenotype.
© 2014 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24891139      PMCID: PMC4827147          DOI: 10.1002/ana.24191

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  51 in total

1.  Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study.

Authors:  David J Schretlen; Mark Varvaris; Tiffany E Ho; Tracy D Vannorsdall; Barry Gordon; James C Harris; H A Jinnah
Journal:  Lancet Neurol       Date:  2013-12       Impact factor: 44.182

2.  Purine metabolism during neuronal differentiation: the relevance of purine synthesis and recycling.

Authors:  Martin Göttle; Heike Burhenne; Diane Sutcliffe; H A Jinnah
Journal:  J Neurochem       Date:  2013-08-18       Impact factor: 5.372

3.  Levodopa is not a useful treatment for Lesch-Nyhan disease.

Authors:  Jasper E Visser; David J Schretlen; Bastiaan R Bloem; Hyder A Jinnah
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

Review 4.  The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases.

Authors:  H A Jinnah; L De Gregorio; J C Harris; W L Nyhan; J P O'Neill
Journal:  Mutat Res       Date:  2000-10       Impact factor: 2.433

5.  Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis.

Authors:  Irene Ceballos-Picot; Lionel Mockel; Marie-Claude Potier; Luce Dauphinot; Thomas L Shirley; Raoul Torero-Ibad; Julia Fuchs; H A Jinnah
Journal:  Hum Mol Genet       Date:  2009-04-02       Impact factor: 6.150

Review 6.  The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome.

Authors:  A A Baumeister; G D Frye
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

7.  Tetrahydrobiopterin deficiency and dopamine loss in a genetic mouse model of Lesch-Nyhan disease.

Authors:  K Hyland; S Kasim; K Egami; L A Arnold; H A Jinnah
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

Review 9.  Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death.

Authors:  Kambiz N Alavian; Christian Scholz; Horst H Simon
Journal:  Mov Disord       Date:  2008-02-15       Impact factor: 10.338

Review 10.  Developmental origins of brain disorders: roles for dopamine.

Authors:  Kelli M Money; Gregg D Stanwood
Journal:  Front Cell Neurosci       Date:  2013-12-19       Impact factor: 5.505

View more
  13 in total

1.  Altered gastrointestinal motility in an animal model of Lesch-Nyhan disease.

Authors:  Maria G Zizzo; Monica Frinchi; Domenico Nuzzo; Hyder A Jinnah; Giuseppa Mudò; Daniele F Condorelli; Francesco Caciagli; Renata Ciccarelli; Patrizia Di Iorio; Flavia Mulè; Natale Belluardo; Rosa Serio
Journal:  Auton Neurosci       Date:  2017-12-20       Impact factor: 3.145

2.  Hypoxanthine Intrastriatal Administration Alters Neuroinflammatory Profile and Redox Status in Striatum of Infant and Young Adult Rats.

Authors:  Helena Biasibetti; Paula Pierozan; André Felipe Rodrigues; Vanusa Manfredini; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2016-03-24       Impact factor: 5.590

3.  Hypoxanthine deregulates genes involved in early neuronal development. Implications in Lesch-Nyhan disease pathogenesis.

Authors:  R J Torres; J G Puig
Journal:  J Inherit Metab Dis       Date:  2015-05-05       Impact factor: 4.982

Review 4.  Encephalomalacia/gliosis, deep venous thrombosis, and cancer in Arg393His antithrombin Hanoi and the potential impact of the β-amyloid precursor protein (APP) on thrombosis and cancer.

Authors:  Khue Vu Nguyen
Journal:  AIMS Neurosci       Date:  2022-04-21

5.  HGprt deficiency disrupts dopaminergic circuit development in a genetic mouse model of Lesch-Nyhan disease.

Authors:  J E Visser; S M Kolk; J S Witteveen; S R Loopstok; L Luque Ballesteros; A Boonstra; N H M van Bakel; W H P van Boekel; G J M Martens
Journal:  Cell Mol Life Sci       Date:  2022-06-04       Impact factor: 9.207

6.  Microstructural white matter abnormalities in Lesch-Nyhan disease.

Authors:  Victor A Del Bene; Jeffrey L Crawford; Ainara Gómez-Gastiasoro; Tracy D Vannorsdall; Alison Buchholz; Natalia Ojeda; James C Harris; Hyder A Jinnah; David J Schretlen
Journal:  Eur J Neurosci       Date:  2021-12-06       Impact factor: 3.698

7.  Consequences of impaired purine recycling on the proteome in a cellular model of Lesch-Nyhan disease.

Authors:  Eric B Dammer; Martin Göttle; Duc M Duong; John Hanfelt; Nicholas T Seyfried; H A Jinnah
Journal:  Mol Genet Metab       Date:  2015-03-05       Impact factor: 4.797

8.  Reduced Number of Pigmented Neurons in the Substantia Nigra of Dystonia Patients? Findings from Extensive Neuropathologic, Immunohistochemistry, and Quantitative Analyses.

Authors:  Diego Iacono; Maria Geraci-Erck; Hui Peng; Marcie L Rabin; Roger Kurlan
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-05-13

Review 9.  Nucleotide salvage deficiencies, DNA damage and neurodegeneration.

Authors:  Michael Fasullo; Lauren Endres
Journal:  Int J Mol Sci       Date:  2015-04-27       Impact factor: 5.923

10.  Lesch-Nyhan disease causes impaired energy metabolism and reduced developmental potential in midbrain dopaminergic cells.

Authors:  Scott Bell; Vincent McCarty; Huashan Peng; Malvin Jefri; Nuwan Hettige; Lilit Antonyan; Liam Crapper; Liam A O'Leary; Xin Zhang; Ying Zhang; Hanrong Wu; Diane Sutcliffe; Ilaria Kolobova; Thad A Rosenberger; Luc Moquin; Alain Gratton; Jelena Popic; Ilse Gantois; Patrick S Stumpf; Andreas A Schuppert; Naguib Mechawar; Nahum Sonenberg; Michel L Tremblay; Hyder A Jinnah; Carl Ernst
Journal:  Stem Cell Reports       Date:  2021-07-01       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.